Switch to:
Also traded in: Argentina, Brazil, Chile, France, Germany, Mexico, Romania, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.50
MRK's Cash to Debt is ranked lower than
76% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.45 vs. MRK: 0.50 )
Ranked among companies with meaningful Cash to Debt only.
MRK' s Cash to Debt Range Over the Past 10 Years
Min: 0.32  Med: 0.68 Max: 2.45
Current: 0.5
0.32
2.45
Equity to Asset 0.44
MRK's Equity to Asset is ranked lower than
75% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. MRK: 0.44 )
Ranked among companies with meaningful Equity to Asset only.
MRK' s Equity to Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.44 Max: 0.53
Current: 0.44
0.34
0.53
Interest Coverage 10.67
MRK's Interest Coverage is ranked lower than
63% of the 467 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.06 vs. MRK: 10.67 )
Ranked among companies with meaningful Interest Coverage only.
MRK' s Interest Coverage Range Over the Past 10 Years
Min: 3.31  Med: 9.85 Max: 20.11
Current: 10.67
3.31
20.11
F-Score: 7
Z-Score: 3.05
M-Score: -2.75
WACC vs ROIC
6.75%
10.57%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 18.42
MRK's Operating margin (%) is ranked higher than
79% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. MRK: 18.42 )
Ranked among companies with meaningful Operating margin (%) only.
MRK' s Operating margin (%) Range Over the Past 10 Years
Min: 5.15  Med: 15.81 Max: 21.86
Current: 18.42
5.15
21.86
Net-margin (%) 11.72
MRK's Net-margin (%) is ranked higher than
69% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.15 vs. MRK: 11.72 )
Ranked among companies with meaningful Net-margin (%) only.
MRK' s Net-margin (%) Range Over the Past 10 Years
Min: 1.87  Med: 13.30 Max: 47.04
Current: 11.72
1.87
47.04
ROE (%) 10.11
MRK's ROE (%) is ranked higher than
60% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. MRK: 10.11 )
Ranked among companies with meaningful ROE (%) only.
MRK' s ROE (%) Range Over the Past 10 Years
Min: 1.52  Med: 14.91 Max: 42.27
Current: 10.11
1.52
42.27
ROA (%) 4.50
MRK's ROA (%) is ranked higher than
53% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.76 vs. MRK: 4.50 )
Ranked among companies with meaningful ROA (%) only.
MRK' s ROA (%) Range Over the Past 10 Years
Min: 0.79  Med: 6.50 Max: 16.34
Current: 4.5
0.79
16.34
ROC (Joel Greenblatt) (%) 46.34
MRK's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 762 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.16 vs. MRK: 46.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MRK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 10.88  Med: 45.71 Max: 105.49
Current: 46.34
10.88
105.49
Revenue Growth (3Y)(%) -3.30
MRK's Revenue Growth (3Y)(%) is ranked lower than
75% of the 602 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. MRK: -3.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MRK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -24  Med: 3.60 Max: 23.1
Current: -3.3
-24
23.1
EBITDA Growth (3Y)(%) -6.40
MRK's EBITDA Growth (3Y)(%) is ranked lower than
74% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. MRK: -6.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MRK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -15.7  Med: 6.10 Max: 25.8
Current: -6.4
-15.7
25.8
EPS Growth (3Y)(%) -7.90
MRK's EPS Growth (3Y)(%) is ranked lower than
69% of the 503 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. MRK: -7.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MRK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -43  Med: 0.20 Max: 74.6
Current: -7.9
-43
74.6
» MRK's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

MRK Guru Trades in Q2 2015

David Dreman 11,463 sh (New)
Ray Dalio 17,141 sh (New)
Kyle Bass 35,404 sh (New)
Manning & Napier Advisors, Inc 6,347,239 sh (+1493.37%)
Jim Simons 1,921,734 sh (+60.93%)
PRIMECAP Management 2,042,000 sh (+47.44%)
Charles Brandes 2,817,473 sh (+26.81%)
Pioneer Investments 3,279,231 sh (+19.08%)
Vanguard Health Care Fund 45,748,498 sh (+14.09%)
Barrow, Hanley, Mewhinney & Strauss 25,641,122 sh (+4.81%)
Ken Fisher 6,836,547 sh (+2.35%)
Murray Stahl 41,151 sh (+0.24%)
Prem Watsa 12,000 sh (unchged)
Robert Bruce 259,400 sh (unchged)
First Eagle Investment 9,050 sh (unchged)
Richard Snow 5,375 sh (unchged)
Tom Russo 3,836 sh (unchged)
Ruane Cunniff 4,784 sh (unchged)
T Rowe Price Equity Income Fund 6,625,700 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt Sold Out
Jeff Auxier 145,134 sh (-0.14%)
Kahn Brothers 1,016,613 sh (-1.28%)
Mairs and Power 102,874 sh (-2.17%)
Dodge & Cox 24,680,781 sh (-3.02%)
NWQ Managers 73,790 sh (-3.27%)
Mario Gabelli 148,540 sh (-7.71%)
RS Investment Management 747,565 sh (-16.78%)
Jeremy Grantham 6,500 sh (-27.15%)
Paul Tudor Jones 16,900 sh (-82.59%)
» More
Q3 2015

MRK Guru Trades in Q3 2015

Joel Greenblatt 5,844 sh (New)
Richard Snow 860,145 sh (+15902.70%)
Ray Dalio 251,746 sh (+1368.68%)
Paul Tudor Jones 44,663 sh (+164.28%)
PRIMECAP Management 2,645,000 sh (+29.53%)
Vanguard Health Care Fund 49,743,388 sh (+8.73%)
Murray Stahl 43,271 sh (+5.15%)
Pioneer Investments 3,427,061 sh (+4.51%)
Ruane Cunniff 4,994 sh (+4.39%)
Mairs and Power 104,124 sh (+1.22%)
David Carlson 250,000 sh (unchged)
Prem Watsa 12,000 sh (unchged)
First Eagle Investment 9,050 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Kyle Bass Sold Out
RS Investment Management Sold Out
David Dreman Sold Out
Tom Russo Sold Out
Dodge & Cox 24,585,258 sh (-0.39%)
T Rowe Price Equity Income Fund 6,571,200 sh (-0.82%)
Charles Brandes 2,791,984 sh (-0.90%)
Kahn Brothers 1,006,208 sh (-1.02%)
Ken Fisher 6,761,706 sh (-1.09%)
Barrow, Hanley, Mewhinney & Strauss 25,179,076 sh (-1.80%)
Jeff Auxier 141,489 sh (-2.51%)
Manning & Napier Advisors, Inc 6,178,367 sh (-2.66%)
Mario Gabelli 142,715 sh (-3.92%)
Signature Select Canadian Fund 154,400 sh (-4.28%)
NWQ Managers 69,835 sh (-5.36%)
Jim Simons 1,461,734 sh (-23.94%)
Jeremy Grantham 4,200 sh (-35.38%)
» More
Q4 2015

MRK Guru Trades in Q4 2015

John Buckingham 24,665 sh (New)
Tom Russo 3,836 sh (New)
Joel Greenblatt 753,471 sh (+12793.07%)
Jim Simons 1,752,234 sh (+19.87%)
Richard Snow 998,514 sh (+16.09%)
Jeff Auxier 153,403 sh (+8.42%)
Charles Brandes 3,012,572 sh (+7.90%)
Barrow, Hanley, Mewhinney & Strauss 26,655,176 sh (+5.86%)
PRIMECAP Management 2,790,000 sh (+5.48%)
Vanguard Health Care Fund 50,476,700 sh (+1.47%)
Ken Fisher 6,822,070 sh (+0.89%)
Mairs and Power 104,637 sh (+0.49%)
Kahn Brothers 1,010,927 sh (+0.47%)
Jeremy Grantham 4,200 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Ruane Cunniff 4,994 sh (unchged)
David Carlson 250,000 sh (unchged)
Prem Watsa Sold Out
Dodge & Cox 24,563,150 sh (-0.09%)
Murray Stahl 43,031 sh (-0.55%)
NWQ Managers 68,615 sh (-1.75%)
Mario Gabelli 139,615 sh (-2.17%)
Paul Tudor Jones 40,561 sh (-9.18%)
First Eagle Investment 7,790 sh (-13.92%)
T Rowe Price Equity Income Fund 5,610,000 sh (-14.63%)
Ray Dalio 156,246 sh (-37.94%)
Pioneer Investments 989,884 sh (-71.12%)
Manning & Napier Advisors, Inc 578,810 sh (-90.63%)
» More
Q1 2016

MRK Guru Trades in Q1 2016

David Dreman 710 sh (New)
Richard Pzena 921,365 sh (New)
John Burbank 1,370,117 sh (New)
Paul Tudor Jones 714,430 sh (+1661.37%)
First Eagle Investment 16,090 sh (+106.55%)
Joel Greenblatt 1,248,557 sh (+65.71%)
Ray Dalio 210,746 sh (+34.88%)
PRIMECAP Management 2,992,800 sh (+7.27%)
Murray Stahl 45,497 sh (+5.73%)
John Buckingham 25,885 sh (+4.95%)
Barrow, Hanley, Mewhinney & Strauss 26,663,511 sh (+0.03%)
Tom Russo 3,836 sh (unchged)
David Carlson 250,000 sh (unchged)
Robert Bruce 259,400 sh (unchged)
NWQ Managers Sold Out
Jeremy Grantham Sold Out
Jeff Auxier 153,303 sh (-0.07%)
Dodge & Cox 24,543,704 sh (-0.08%)
Charles Brandes 3,000,058 sh (-0.42%)
Ken Fisher 6,698,235 sh (-1.82%)
Ruane Cunniff 4,894 sh (-2.00%)
Kahn Brothers 985,419 sh (-2.52%)
Mairs and Power 101,850 sh (-2.66%)
Vanguard Health Care Fund 48,728,100 sh (-3.46%)
Pioneer Investments 925,463 sh (-6.51%)
Richard Snow 911,027 sh (-8.76%)
Manning & Napier Advisors, Inc 501,558 sh (-13.35%)
Mario Gabelli 118,145 sh (-15.38%)
T Rowe Price Equity Income Fund 4,702,900 sh (-16.17%)
Jim Simons 484,334 sh (-72.36%)
» More
» Details

Insider Trades

Latest Guru Trades with MRK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:JNJ, NYSE:PFE, XSWX:NOVN, NYSE:BMY, XPAR:SAN » details
Traded in other countries:MRK.Argentina, MRCK34.Brazil, MRK.Chile, MRK.France, 6MK.Germany, MRK.Mexico, MRK.Romania, MRK.Switzerland, 0QAH.UK,
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.

Merck & Co Inc was incorporated in New Jersey in 1970. The Company is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company's operations are mainly managed on a products basis and are comprised of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. Additionally, the Company has consumer care operations that develop, manufacture and market over-the-counter, foot care and sun care products, which are sold through wholesale and retail drug, food chain and mass merchandiser outlets, as well as club stores and specialty channels. The Company's competitors include other worldwide research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, and generic drug and consumer health care manufacturers. The Company's activities, including research, preclinical testing, clinical trials and manufacturing and marketing its products, are subject to regulation by numerous federal, state and local governmental authorities in the United States, including the FDA, and by foreign regulatory authorities, including the European Commission.

Top Ranked Articles about Merck & Co Inc

Merck CEO Kenneth Frazier Sells 131,040 Shares Merck has 2 products recently approved by FDA
Kenneth Frazier (Insider Trades), CEO, president and chairman of Merck & Co. Inc. (MRK), sold 131,040 shares of the company on April 14. The average price per share was $56.11 for a total transaction cost of $7,352,654. Merck is a pharmaceuticals company that provides prescription medicines, vaccines, biologic therapies and animal health products worldwide. The company has a market cap of $155.49 billion and a P/S ratio of 3.97. Read more...
5 Guru Picks in Volatile Biotech Industry Johnson & Johnson and Merck each have the backing of more than 25 gurus
Biotech and pharmaceutical stocks made some of the biggest headlines this year, as 2015 saw massive waves of M&A activity, including the Pfizer (NYSE:PFE) and Allergan (NYSE:AGN) merger, the second-largest deal of all time valued at $160 billion. Other companies found themselves in the spotlight for less than desirable reasons, such as Valeant Pharmaceuticals (NYSE:VRX), whose stock has tanked in the past several months. Read more...
Merck & Co. Versus AbbVie: Who Is the Winner and Who Is the Loser? The question that needs to be asked about AbbVie's demise is: What caused the earnings decline in the last five years after it went public?
Merck & Co. (NYSE: MRK) and AbbVie Inc. (NYSE: ABBV) are two very different companies and face very different situations when it comes to earnings and growth, not to mention one is significantly older than the other. From 2009 to 2010, Merck's earnings fell by 14 times what they previously were but have made a comeback and have leveled out while AbbVie has only been public since 2013 and in its short history as a public has seen its earnings plunge by 20.31% annually. Merck's earnings have stayed consistent since its earnings recovered from 26 cents in December 2010 to $3.74 currently. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 34.10
MRK's P/E(ttm) is ranked lower than
59% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.44 vs. MRK: 34.10 )
Ranked among companies with meaningful P/E(ttm) only.
MRK' s P/E(ttm) Range Over the Past 10 Years
Min: 6.67  Med: 18.66 Max: 139.89
Current: 34.1
6.67
139.89
Forward P/E 14.60
MRK's Forward P/E is ranked lower than
53% of the 90 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.95 vs. MRK: 14.60 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 34.10
MRK's PE(NRI) is ranked lower than
58% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.81 vs. MRK: 34.10 )
Ranked among companies with meaningful PE(NRI) only.
MRK' s PE(NRI) Range Over the Past 10 Years
Min: 6.65  Med: 18.62 Max: 133.39
Current: 34.1
6.65
133.39
Price/Owner Earnings (ttm) 18.21
MRK's Price/Owner Earnings (ttm) is ranked higher than
74% of the 265 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.19 vs. MRK: 18.21 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MRK' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.92  Med: 14.60 Max: 40.64
Current: 18.21
5.92
40.64
P/B 3.48
MRK's P/B is ranked lower than
61% of the 762 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. MRK: 3.48 )
Ranked among companies with meaningful P/B only.
MRK' s P/B Range Over the Past 10 Years
Min: 1.72  Med: 3.22 Max: 7.25
Current: 3.48
1.72
7.25
P/S 3.97
MRK's P/S is ranked lower than
61% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. MRK: 3.97 )
Ranked among companies with meaningful P/S only.
MRK' s P/S Range Over the Past 10 Years
Min: 2.02  Med: 3.21 Max: 5.48
Current: 3.97
2.02
5.48
PFCF 14.44
MRK's PFCF is ranked higher than
75% of the 199 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.71 vs. MRK: 14.44 )
Ranked among companies with meaningful PFCF only.
MRK' s PFCF Range Over the Past 10 Years
Min: 7.87  Med: 15.70 Max: 89.14
Current: 14.44
7.87
89.14
POCF 12.80
MRK's POCF is ranked higher than
67% of the 265 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.71 vs. MRK: 12.80 )
Ranked among companies with meaningful POCF only.
MRK' s POCF Range Over the Past 10 Years
Min: 6.67  Med: 12.82 Max: 35.89
Current: 12.8
6.67
35.89
EV-to-EBIT 26.38
MRK's EV-to-EBIT is ranked lower than
64% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.64 vs. MRK: 26.38 )
Ranked among companies with meaningful EV-to-EBIT only.
MRK' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 14.10 Max: 52.6
Current: 26.38
4.9
52.6
EV-to-EBITDA 13.21
MRK's EV-to-EBITDA is ranked higher than
64% of the 569 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.81 vs. MRK: 13.21 )
Ranked among companies with meaningful EV-to-EBITDA only.
MRK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.2  Med: 8.40 Max: 20.4
Current: 13.21
4.2
20.4
PEG 3.67
MRK's PEG is ranked lower than
69% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. MRK: 3.67 )
Ranked among companies with meaningful PEG only.
MRK' s PEG Range Over the Past 10 Years
Min: 0.55  Med: 2.61 Max: 28.4
Current: 3.67
0.55
28.4
Shiller P/E 21.83
MRK's Shiller P/E is ranked higher than
79% of the 146 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 46.77 vs. MRK: 21.83 )
Ranked among companies with meaningful Shiller P/E only.
MRK' s Shiller P/E Range Over the Past 10 Years
Min: 7.53  Med: 15.10 Max: 24.57
Current: 21.83
7.53
24.57
Current Ratio 1.64
MRK's Current Ratio is ranked lower than
68% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. MRK: 1.64 )
Ranked among companies with meaningful Current Ratio only.
MRK' s Current Ratio Range Over the Past 10 Years
Min: 1.07  Med: 1.59 Max: 3.7
Current: 1.64
1.07
3.7
Quick Ratio 1.35
MRK's Quick Ratio is ranked lower than
65% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.87 vs. MRK: 1.35 )
Ranked among companies with meaningful Quick Ratio only.
MRK' s Quick Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.26 Max: 3.44
Current: 1.35
0.8
3.44
Days Inventory 125.94
MRK's Days Inventory is ranked lower than
57% of the 668 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.30 vs. MRK: 125.94 )
Ranked among companies with meaningful Days Inventory only.
MRK' s Days Inventory Range Over the Past 10 Years
Min: 104.23  Med: 130.49 Max: 205.17
Current: 125.94
104.23
205.17
Days Sales Outstanding 63.48
MRK's Days Sales Outstanding is ranked higher than
60% of the 620 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.15 vs. MRK: 63.48 )
Ranked among companies with meaningful Days Sales Outstanding only.
MRK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.5  Med: 58.77 Max: 87.87
Current: 63.48
44.5
87.87
Days Payable 54.76
MRK's Days Payable is ranked lower than
63% of the 589 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 71.47 vs. MRK: 54.76 )
Ranked among companies with meaningful Days Payable only.
MRK' s Days Payable Range Over the Past 10 Years
Min: 30.2  Med: 44.78 Max: 90.82
Current: 54.76
30.2
90.82

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.26
MRK's Dividend Yield is ranked higher than
80% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. MRK: 3.26 )
Ranked among companies with meaningful Dividend Yield only.
MRK' s Dividend Yield Range Over the Past 10 Years
Min: 2.51  Med: 3.90 Max: 6.68
Current: 3.26
2.51
6.68
Dividend Payout 1.11
MRK's Dividend Payout is ranked lower than
72% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. MRK: 1.11 )
Ranked among companies with meaningful Dividend Payout only.
MRK' s Dividend Payout Range Over the Past 10 Years
Min: 0.16  Med: 0.51 Max: 3.8
Current: 1.11
0.16
3.8
Dividend Growth (3y) 2.30
MRK's Dividend Growth (3y) is ranked lower than
63% of the 283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. MRK: 2.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
MRK' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 2.80 Max: 14.8
Current: 2.3
0
14.8
Forward Dividend Yield 3.35
MRK's Forward Dividend Yield is ranked higher than
77% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. MRK: 3.35 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.91
MRK's Yield on cost (5-Year) is ranked higher than
75% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.95 vs. MRK: 3.91 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MRK' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.01  Med: 4.68 Max: 8.01
Current: 3.91
3.01
8.01
3-Year Average Share Buyback Ratio 2.80
MRK's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 425 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. MRK: 2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MRK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13  Med: 1.10 Max: 2.8
Current: 2.8
-13
2.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 33.10
MRK's Price/Tangible Book is ranked lower than
97% of the 708 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. MRK: 33.10 )
Ranked among companies with meaningful Price/Tangible Book only.
MRK' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.19  Med: 12.79 Max: 3112.5
Current: 33.1
3.19
3112.5
Price/Projected FCF 1.26
MRK's Price/Projected FCF is ranked higher than
79% of the 311 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. MRK: 1.26 )
Ranked among companies with meaningful Price/Projected FCF only.
MRK' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.75  Med: 1.23 Max: 3.04
Current: 1.26
0.75
3.04
Price/Median PS Value 1.24
MRK's Price/Median PS Value is ranked lower than
59% of the 680 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. MRK: 1.24 )
Ranked among companies with meaningful Price/Median PS Value only.
MRK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.66  Med: 1.23 Max: 2.03
Current: 1.24
0.66
2.03
Price/Peter Lynch Fair Value 3.85
MRK's Price/Peter Lynch Fair Value is ranked lower than
88% of the 173 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. MRK: 3.85 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MRK' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.58  Med: 1.64 Max: 10.1
Current: 3.85
0.58
10.1
Price/Graham Number 7.08
MRK's Price/Graham Number is ranked lower than
91% of the 432 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. MRK: 7.08 )
Ranked among companies with meaningful Price/Graham Number only.
MRK' s Price/Graham Number Range Over the Past 10 Years
Min: 1.08  Med: 3.64 Max: 32.76
Current: 7.08
1.08
32.76
Earnings Yield (Greenblatt) (%) 3.80
MRK's Earnings Yield (Greenblatt) (%) is ranked higher than
56% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. MRK: 3.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MRK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.9  Med: 7.10 Max: 20.6
Current: 3.8
1.9
20.6
Forward Rate of Return (Yacktman) (%) 14.35
MRK's Forward Rate of Return (Yacktman) (%) is ranked higher than
64% of the 323 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.36 vs. MRK: 14.35 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MRK' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -5.7  Med: 6.30 Max: 22.2
Current: 14.35
-5.7
22.2

More Statistics

Revenue (TTM) (Mil) $39,385
EPS (TTM) $ 1.63
Beta0.75
Short Percentage of Float1.00%
52-Week Range $45.69 - 61.70
Shares Outstanding (Mil)2,768.03

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 39,248 38,823 40,164
EPS ($) 3.70 3.76 3.91
EPS without NRI ($) 3.70 3.76 3.91
EPS Growth Rate
(3Y to 5Y Estimate)
4.25%
» More Articles for MRK

Headlines

Articles On GuruFocus.com
The PBM Empire Strikes Back May 10 2016 
U.S. Stocks Trade Flat at Start of Week May 09 2016 
Market Indexes Flat as Economic Indicators Still Point Lower May 08 2016 
UnitedHealth’s Obamacare Changes to Affect Healthcare Sector Apr 27 2016 
Merck CEO Kenneth Frazier Sells 131,040 Shares Apr 15 2016 
Manning & Napier Sells Chunks of Stakes in GE, Eli Lilly, Merck Mar 29 2016 
An Attempt to Value Valeant Just for Fun Mar 23 2016 
Whole Foods' Green Initiatives Will Pay Off for Investors Mar 22 2016 
Amgen: Should I Just Sit and Wait? Mar 18 2016 
Sanofi's New Products Will Fuel Sales Mar 13 2016 

More From Other Websites
Merck Announces Third-Quarter 2016 Dividend May 24 2016
Merck Announces Third-Quarter 2016 Dividend May 24 2016
Monsanto: A 'Once in a Lifetime Opportunity?' May 24 2016
Merck to Present at the UBS Global Healthcare Conference May 24 2016
Merck to Present at the UBS Global Healthcare Conference May 24 2016
6:20 am Merck Animal Health receives marketing authorization from European Medicines Agency for... May 24 2016
MSD Animal Health Receives Marketing Approval from European Medicines Agency for BRAVECTO™... May 24 2016
Merck Showcases Innovative Effect Pigments and Printing Technologies at Drupa 2016 May 24 2016
[$$] Bayer Makes $62 Billion Bid for Monsanto May 23 2016
Merck Announces FDA Accepts Samsung Bioepis’ Biologics License Application (BLA) for SB2... May 23 2016
[$$] Germany's Bayer Offers $62 Billion in Cash for Monsanto May 23 2016
Rlypsa Stock Pops on New Data and a Huge Risk May 23 2016
Merck Foundation Announces the Alliance to Advance Patient-Centered Cancer Care, a $15 Million... May 23 2016
Merck Foundation Announces the Alliance to Advance Patient-Centered Cancer Care, a $15 Million... May 23 2016
A Rudderless Market May 23 2016
China's drugs watchdog struggles as senior staff lured away by industry May 22 2016
Gilead Sciences: Where Do We Go From Here? May 20 2016
Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View May 20 2016
Keytruda: Merck’s Immuno-Oncology Blockbuster Drug May 20 2016
Merck and the GIZ Cooperate in Africa May 20 2016
Biggest German Deals: Bayer Hopes to Dodge Daimler-Chrysler Fate May 19 2016
Fed Should Not Raise Rates Now May 19 2016
We Will Deliver Sigma Synergies For 2016, Vows Merck CFO May 19 2016
Merck Increases Sales and Earnings in Q1 Following Sigma-Aldrich Acquisition May 19 2016
Will Merck’s Recent New Developments Make a Difference? May 18 2016
The Reasons behind Merck’s Improving Profitability May 18 2016
Merck KGaA, Darmstadt, Germany, and Pfizer to Present Avelumab Data in Seven Different Cancers at... May 18 2016
New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including... May 18 2016
New Hope for Melanoma Patients May 18 2016
New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including... May 18 2016
Bringing Innovation to Patients: Merck Presents New Advances at ASCO 2016 May 18 2016
Merck and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting May 18 2016
Amgen Researchers Find Gene That Reduces Heart Attack Risk May 18 2016
New KEYTRUDA® (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival... May 16 2016
German Image Award Goes to former Merck CEO Karl-Ludwig Kley and former Chief Communications Officer... May 13 2016
Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th... May 12 2016
Merck Expands Popular Line of Guava® Flow Cytometers May 11 2016
Merck Showcases New Innovations at Analytica 2016 May 10 2016
Merck High-Tech for the Automotive Industry May 10 2016
Merck and Progyny Extend Collaboration for Eeva® Software to Global Level May 09 2016
Merck Launches First Commercially Available Equine-Specific Multiplex Assay for Protein Biomarkers May 09 2016
Business Highlights May 05 2016
Merck beats 1Q profit views with tight cost controls May 05 2016
Merck Announces First-Quarter 2016 Financial Results May 05 2016
New tests for choosing right hep C drug could save money Apr 14 2016
A look at Bayer AG Apr 01 2016
Experts warn complacency on Ebola may leave vaccine work unfinished Mar 31 2016
Business Highlights Mar 25 2016
Jury: Gilead owes Merck $200M in damages over drug patents Mar 25 2016
Jury finds for Merck in hepatitis drug fight with Gilead Mar 22 2016
Asian markets mixed ahead of Fed decision, China meeting Mar 15 2016
Merck, Sanofi Pasteur ending JV to market vaccines in Europe Mar 08 2016
Merck, Sanofi Pasteur ending JV to market vaccines in Europe Mar 08 2016
Study: $3B will be wasted on unused portion of cancer drugs Mar 01 2016
Rivals chase Bristol-Myers in cancer immunotherapy drug race Feb 26 2016
Small study suggests ZMapp may boost Ebola virus survival Feb 24 2016
Merck KGaA says consumer health saw 'nice' growth in 2015 Feb 23 2016
UK watchdog fines GSK $54 mln over 'pay-for-delay' drug deals Feb 12 2016
FDA panel backs lower-cost version of J&J's top-selling drug Feb 09 2016
Merck beats 4Q profit forecast, misses Street view on sales Feb 03 2016
FDA OKs Merck hepatitis C drug, adding to patient choices Jan 28 2016
Gavi signs $5bn Ebola vaccine deal Jan 20 2016
Global Vaccine promises $5 million to develop Ebola vaccine Jan 20 2016
Fight over Merck name sees German firm win in British court Jan 15 2016
Merck pays $830 M to settle class-action case over Vioxx Jan 15 2016
Merck Acquires IOmet Pharma and Expands Immuno-Oncology Development Program Jan 11 2016
Merck CEO: Eager for deals, strong prospects for new drugs Jan 05 2016
Lufthansa plays down report about new chairman Dec 17 2015
Pfizer set to buy Allergan for more than $150 bln-sources Nov 22 2015
Ex-BNY Mellon employee sentenced to 6 months in U.S. prison Nov 12 2015
GSK heart drug flops in study, shingles vaccine on track Oct 27 2015
KEYTRUDA® (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and... Oct 09 2015
BUZZ-Lilly shares add to gains after diabetes drug finding Sep 17 2015
UK backs use of Merck cancer immunotherapy after price discount Sep 07 2015
Only two Ebola cases reported in past week, but risks remain - WHO Aug 04 2015
After Merck success, work goes on with other Ebola vaccines Jul 31 2015
Cancer immunomodulators market players Merck and Dynavax announce partnership for clinical trials Jun 16 2015
Consumerization Drives Growth at Merck Consumer Health Jun 09 2015
UPDATE 1-U.S. bird flu causes egg shortage, emergency measures May 23 2015
U.S. bird flu causes egg shortage, emergency measures May 22 2015
U.S. bird flu causing egg squeeze, emergency measures May 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)